Dräger makes changes to Executive Board

Carla Kriwet will take responsibility for marketing and sales on 1 January 2011

The Supervisory Board of Drägerwerk Verwaltungs has appointed Dr Carla Kriwet as a new Executive Board member, who will take responsibility for marketing and sales on 1 January 2011.

Kriwet currently works for Linde Group as head of Healthcare Europe for the Division Hospital Care and Homecare in Central and Northern Europe.



Dr Dieter Pruss, currently responsible for marketing and sales for the safety division on the Executive Board, will leave the company at his own request on 31 December, 2010, to take on new challenges. 


You may also like

Personal Protection

Draeger introduces X-plore 8000 powered air purifying respirator

To help workers in the pharmaceutical sector breathe easy in harsh environments

DRAEGER OFFERS FREE COPIES OF NEW DRÄGERTUBE HANDBOOK

<p>Draeger is offering a free copy of the new DraegerTubes & CMS-Handbook to anyone with a need for short term gas detection. Available whilst stocks last, this 15th edition is packed with the latest information on more than 350 DraegerTubes and represents a definitive guide to the selection and use of short term tubes in line with current legislation.</p>

Easy infra-red upgrade and longer sensor life with explosion-proof Draeger Sensor IR

<p>Upgrading to infra-red technology has never been easier, or more cost effective, than with the longer-life, explosion-proof Draeger Sensor IR. </p>
Sustainability

Explosion-proof transmitter from Draeger

<p>Draeger Safety has launched the Draeger PIR 3000, a smart explosion proof infra-red gas transmitter that the company says ensures reliable detection of combustible gases and vapours.</p>
Cell & Gene Therapy

iOrganBio launches with $2m seed round and unveils CellForge, the first AI-powered cell manufacturing platform

Founded by experts in stem cell biology, organoid systems and biomedical engineering, the company aims to revolutionise how human cells are designed and produced for drug discovery and regenerative medicine
Regulatory

NICE backs generic abiraterone for advanced prostate cancer in move set to benefit thousands and save NHS millions

New draft guidance recommends abiraterone for adults with newly diagnosed high-risk metastatic prostate cancer, marking a major shift driven by lower-cost generics and a more dynamic approach to keeping NHS care up to date
Pharma 5.0

Pistoia Alliance launches Phase 3 of CMC Process Ontology to bridge life sciences data gap and accelerate AI adoption

Backed by major pharma companies, the initiative aims to standardise experimental and process data across R&D and manufacturing, enabling automation and AI-ready data throughout the life sciences industry
Subscribe now